Screening strategies | Lifetime screening outcomes per 1000 individuals | |||||
---|---|---|---|---|---|---|
GC deaths predicteda | GC deaths reduction, %b | Number of endoscopiesa | QALYs gainedb,c | Total costs ($1000)c | ICER ($ per QALY gained)c,d | |
No screening | 9.1 | 0.0 | 81 | 0.0 | 693 | – |
Current screening guidelines | ||||||
 50–no stopping age, 3 years | 2.3 | 74.8 | 14,516 | 30.1 | 2247 | Dominated |
 50–no stopping age, 2 years | 1.8 | 80.5 | 21,379 | 28.1 | 3091 | Dominated |
Alterative screening strategies | ||||||
 Biennial screening | ||||||
  Initiation at age 50 years | ||||||
   50–75, 2 years | 3.0 | 67.3 | 14,873 | 25.9 | 2662 | Dominated |
   50–80, 2 years | 2.5 | 72.3 | 16,666 | 27.4 | 2798 | Dominated |
  Initiation at age 45 years | ||||||
   45–75, 2 years | 2.7 | 70.3 | 17,237 | 26.4 | 3263 | Dominated |
   45–80, 2 years | 2.0 | 77.9 | 19,928 | 28.6 | 3465 | Dominated |
  Initiation at age 40 years | ||||||
   40–75, 2 years | 2.5 | 72.7 | 20,559 | 25.5 | 4064 | Dominated |
   40–80, 2 years | 2.0 | 77.6 | 22,358 | 26.7 | 4199 | Dominated |
 Triennial screening | ||||||
  Initiation at age 50 years | ||||||
   50–75, 3 years | 3.4 | 63.0 | 9694 | 27.2 | 1934 | 45,665 |
   50–80, 3 years | 2.8 | 69.1 | 11,507 | 29.4 | 2066 | 60,731 |
  Initiation at age 45 years | ||||||
   45–75, 3 years | 3.0 | 67.6 | 11,907 | 30.9 | 2380 | Dominated |
   45–80, 3 years | 2.4 | 73.7 | 13,660 | 32.7 | 2504 | 130,149 |
  Initiation at age 40 years | ||||||
   40–75, 3 years | 2.8 | 69.6 | 14,101 | 31.1 | 2909 | Dominated |
   40–80, 3 years | 2.4 | 73.4 | 15,024 | 31.5 | 2975 | Dominated |